Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add on Therapy in Patients With Cold Contact Urticaria, Symptomatic Dermographism and Cholinergic Urticaria

NCT04548869 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT04548869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04548869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add on Therapy in Patients With Cold Contact Urticaria, Symptomatic Dermographism and Cholinergic Urticaria
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 24, 2020
Completion date
May 12, 2023
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholinergic urticaria, cold contact urticaria, cold urticaria, symptomatic dermatographism, symptomatic dermographism